Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25925101 | 0.87 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1SMN1; SMN2TP53LMNA | |
| SCHEMBL2067150 | 0.83 | CCNC (0.43) | L3MBTL1ALDH1A1HTTSMN1; SMN2TP53 | |
| SCHEMBL1559636 | 0.82 | ALDH1A1 (0.43) | L3MBTL1ALDH1A1TP53LMNA | |
| SCHEMBL1559248 | 0.82 | MITF (0.51) | ALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL25925092 | 0.80 | ALDH1A1 (0.37) | L3MBTL1ALDH1A1GAASMN1; SMN2TP53 | |
| SCHEMBL2066748 | 0.80 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2TP53LMNA | |
| SCHEMBL18463627 | 0.80 | ALDH1A1 (0.52) | L3MBTL1ALDH1A1HTTGAASMN1; SMN2 | |
| SCHEMBL21070507 | 0.78 | MCL1 (0.53) | L3MBTL1ALDH1A1HTTGAASMN1; SMN2 | |
| SCHEMBL16160355 | 0.77 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1HTTGAASMN1; SMN2 | |
| SCHEMBL20555415 | 0.76 | MAPK1 (0.46) | L3MBTL1ALDH1A1HTTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | L3MBTL1 2657/4885ALDH1A1 2405/4885HTT 1605/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | L3MBTL1 2657/4885ALDH1A1 2405/4885HTT 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.